Veracyte Announces Launch of New Afirma Xpression Atlas at 2018 AACE Congress
May 16 2018 - 3:19PM
Business Wire
Veracyte, Inc. (Nasdaq: VCYT) today announced the launch of the
new Afirma Xpression Atlas, an RNA sequencing-based test that
provides extensive genomic information to aid in surgery and
treatment decisions for patients with potentially cancerous thyroid
nodules. The new test is being introduced at the AACE 27th Annual
Scientific & Clinical Congress where robust test performance
data will be shared in a Product Theater event and poster
presentation by Veracyte and external researchers. The AACE meeting
is being held May 16-20 in Boston.
The Afirma Xpression Atlas detects 761 DNA variants and 130 RNA
fusion pairs in over 500 genes that have been linked to thyroid
cancer. In some cases, these gene alterations have demonstrated
association with more aggressive thyroid cancers or with
higher-stage disease.
“For patients who are already going to surgery for suspected
thyroid cancer, the Afirma Xpression Atlas provides additional
genomic information that physicians and patients may use in
decisions about the surgical approach,” said Peter M. Sadow, M.D.,
Ph.D., of Massachusetts General Hospital and Harvard Medical
School. “Additionally, as more is understood about gene alterations
and their impact on thyroid cancer development, prognosis and tumor
pathway dependence, this RNA sequencing information may help to
further guide patient care.” Dr. Sadow will present performance
data for the Xpression Atlas test during a poster session at the
AACE meeting on Saturday, May 19.
The gene variants and fusion partners in the Afirma Xpression
Atlas were derived from the thyroid literature and from The Cancer
Genome Atlas (TCGA). The RNA-sequencing based panel is offered as
an extension to Veracyte’s market-leading Afirma Genomic Sequencing
Classifier (GSC), which is widely used to identify benign nodules
among those deemed indeterminate by cytopathology so that patients
can avoid unnecessary surgery.
“In tandem with our Afirma GSC, the Afirma Xpression Atlas
provides physicians with the most comprehensive and evidence-based
genomic information available to inform diagnosis, stratify thyroid
cancer risk and, for those who are diagnosed with
cancer, aid in therapeutic selection,” said Bonnie Anderson,
Veracyte’s chairman and chief executive officer.
More information about Afirma data being presented at the AACE
meeting can be found at Veracyte’s booth (#707) or at
www.veracyte.com/AACE2018.
About Afirma
Veracyte’s Afirma solution provides a comprehensive solution for
physicians evaluating patients with potentially cancerous thyroid
nodules. The Afirma Genomic Sequencing Classifier combines RNA
sequencing data with machine learning to identify patients with
benign thyroid nodules among those with indeterminate cytopathology
results in order to avoid unnecessary surgery and preserve the
thyroid. Since the commercial introduction of Afirma in 2011,
Veracyte has performed over 100,000 genomic tests, and estimates it
has saved more than 40,000 patients from unnecessary thyroid
surgery and removed an estimated $800 million in surgery costs from
the healthcare system. The Afirma classifier is proven in over 20
published clinical studies, is included in most leading clinical
guidelines and is covered as medically necessary by Medicare and
all major U.S. health plans. The company’s Afirma Xpression Atlas
platform, introduced in May 2018, provides extensive genomic data
that may inform surgery strategy and treatment options for patients
with thyroid nodules that are suspicious for cancer. The RNA
sequencing-based platform measures 761 DNA variants and 130 RNA
fusions in over 500 genes shown to be associated with thyroid
cancer on thyroid nodule fine needle aspiration samples.
About Veracyte
Veracyte, Inc. (Nasdaq: VCYT) is a leading genomic diagnostics
company that is providing trustworthy and actionable answers that
fundamentally improve patient care when current diagnostic tests
are uncertain. The company's products uniquely combine genomic
technology, clinical science and machine learning to provide
answers that give physicians and patients a clear path forward
without risky, costly surgery that is often unnecessary. Since its
founding in 2008, Veracyte has commercialized three genomic tests,
which are transforming the diagnosis of thyroid cancer, lung cancer
and idiopathic pulmonary fibrosis and collectively target a $2
billion market opportunity. Veracyte is based in South San
Francisco, California. For more information, please visit
www.veracyte.com and follow the company on Twitter (@veracyte).
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by words such
as: "anticipate," "intend," "plan," "expect," "believe," "should,"
"may," "will" and similar references to future periods. Examples of
forward-looking statements include, among others, our belief that
our genomic tests will transform the diagnosis of thyroid cancer,
lung cancer and idiopathic pulmonary fibrosis; statements regarding
our Afirma Xpression Atlas platform, which we plan to introduce
soon; and Afirma’s ability to significantly improve patient care
and reduce healthcare costs. Forward-looking statements are neither
historical facts nor assurances of future performance. Instead,
they are based only on our current beliefs, expectations and
assumptions regarding the future of our business, future plans and
strategies, anticipated events and trends, the economy and other
future conditions. Forward-looking statements involve risks and
uncertainties, which could cause actual results to differ
materially, and reported results should not be considered as an
indication of future performance. These risks and uncertainties
include, but are not limited to: the benefits of our tests, the
applicability of clinical results to actual outcomes; the laws and
regulations applicable to our business, including potential
regulation by the Food and Drug Administration or other
regulatory bodies; our ability to sell our Afirma tests and
successfully transition to our next-generation Afirma GSC; our
ability to successfully achieve and maintain adoption of and
reimbursement for our products; the amount by which use of our
products are able to reduce invasive procedures and misdiagnosis,
and reduce healthcare costs; the occurrence and outcomes of
clinical studies; and other risks set forth in our filings with
the Securities and Exchange Commission, including the risks
set forth in our quarterly report on Form 10-Q for the quarter
ended March 31, 2018. These forward-looking statements speak
only as of the date hereof and Veracyte specifically
disclaims any obligation to update these forward-looking statements
or reasons why actual results might differ, whether as a result of
new information, future events or otherwise, except as required by
law.
Veracyte, Afirma, Percepta, Envisia, the Veracyte logo, and the
Afirma logo are trademarks of Veracyte, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180516006368/en/
Veracyte, Inc.Tracy Morris,
650-380-4413tracy.morris@veracyte.comorInvestors:Keith
Kennedy, 650-243-6357Chief Financial Officerkeith@veracyte.com
Veracyte (NASDAQ:VCYT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Veracyte (NASDAQ:VCYT)
Historical Stock Chart
From Sep 2023 to Sep 2024